Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $10.77 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-03
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $8.54M, a 452.07% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $2.06M, a 9.37% decline year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $172.00K, a 96.48% decline year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $1.55M, a 55.34% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month |
|---|---|---|---|
| 2026-06-30 | $8.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | $10.60M derived: sum of 2 quarters · filed 2026-08-03 | $10.77M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $2.06M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | $2.23M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $172.00K 10-Q/A · filed 2026-02-26 | ||
| 2025-06-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-04 | $3.82M derived: sum of 2 quarters · filed 2025-08-04 | $8.70M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-05 | $7.15M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $4.88M 10-Q · filed 2025-02-03 | ||
| 2024-06-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-02 | $4.64M derived: sum of 2 quarters · filed 2024-08-02 | $5.12M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-02 | $1.66M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $483.00K 10-Q · filed 2024-02-02 | ||
| 2023-06-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $577.00K derived: sum of 2 quarters · filed 2023-08-07 | $889.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $327.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | $639.00K 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $312.00K 10-Q · filed 2023-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |